Want to see SRTA full AI Analyst Report?
SRTA Stock Chart & Stats
$5.04
-$0.05(-0.98%)
At close: 4:00 PM EDT
$5.04
-$0.05(-0.98%)
Day’s Range― - ―
52-Week Range$3.69 - $6.50
Previous CloseN/A
Volume1.08M
Average Volume (3M)1.21M
Market Cap
$434.36M
Enterprise Value$322.32
Total Cash (Recent Filing)$22.75M
Total Debt (Recent Filing)$4.25M
Price to Earnings (P/E)―
Beta2.16
Next Earnings
Nov 11, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding86,526,570
10 Day Avg. Volume862,536
30 Day Avg. Volume1,207,404
Financial Highlights & Ratios
PEG Ratio0.55
Price to Book (P/B)1.42
Price to Sales (P/S)2.01
P/FCF Ratio-6.62
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.50Price Target Upside88.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$276.93M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low leverage and a large equity cushion provide durable financial flexibility: the company can fund operations, absorb cash-flow variability, and pursue bolt-on M&A or capex without immediate refinancing stress, reducing solvency risk over the next several quarters.
Clinical Revenue Acceleration & MixRapid, higher-margin clinical growth materially improves revenue mix and gross margin potential. Structural tailwinds (rising NRP penetration and transplant recovery) support sustained demand, helping margins and revenue visibility over the coming 2–6 months as clinical becomes a larger share of revenue.
Accretive M&A And Operational ScaleConsistent, accretive bolt-on acquisitions expand clinical footprint and add immediate EBITDA, accelerating scale benefits. Combined with an integrated logistics ops center and multi-hub fleet, this enhances competitive positioning and supports sustainable margin improvement if integration stays on plan.
Bears Say
Weak Cash GenerationPersistent negative operating and free cash flow implies reported profits are not turning into cash. This forces reliance on the balance sheet, one‑off receipts, or external funding to support operations and growth, constraining reinvestment and increasing financing risk if cash inflection slows.
Core Operating Profitability Still NegativeAlthough net income and net margins improved, negative EBIT/EBITDA indicate core operations are not consistently profitable. Sustained structural improvement is required for durable margin gains; otherwise profitability depends on non‑operational items and one‑time events.
Logistics Margin & Operational RisksFleet maintenance, elevated capex and contract limits on fuel pass-throughs create structural pressure on Logistics margins. Combined with single-customer volume swings, this concentration and operational volatility can depress earnings stability and cash conversion over multiple quarters.
Strata Critical Medical News
SRTA FAQ
What was Strata Critical Medical, Inc.’s price range in the past 12 months?
Strata Critical Medical, Inc. lowest stock price was $3.69 and its highest was $6.50 in the past 12 months.
What is Strata Critical Medical, Inc.’s market cap?
Strata Critical Medical, Inc.’s market cap is $434.36M.
When is Strata Critical Medical, Inc.’s upcoming earnings report date?
Strata Critical Medical, Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 93 days.
How were Strata Critical Medical, Inc.’s earnings last quarter?
Strata Critical Medical, Inc. released its earnings results on Aug 04, 2026. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.02 by -$0.1.
Is Strata Critical Medical, Inc. overvalued?
According to Wall Street analysts Strata Critical Medical, Inc.’s price is currently Undervalued.
Does Strata Critical Medical, Inc. pay dividends?
Strata Critical Medical, Inc. does not currently pay dividends.
What is Strata Critical Medical, Inc.’s EPS estimate?
Strata Critical Medical, Inc.’s EPS estimate is >-0.01.
How many shares outstanding does Strata Critical Medical, Inc. have?
Strata Critical Medical, Inc. has 86,526,570 shares outstanding.
What happened to Strata Critical Medical, Inc.’s price movement after its last earnings report?
Strata Critical Medical, Inc. reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.02. Following the earnings report the stock price went up 0.36%.
Which hedge fund is a major shareholder of Strata Critical Medical, Inc.?
Currently, no hedge funds are holding shares in SRTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Strata Critical Medical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.50 (88.49% Upside)
$9.50 (88.49% Upside)
Blogger Sentiment
Bullish
SRTA Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $420.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.6%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
30.76%
Trailing 12-Months
Company Description
Strata Critical Medical, Inc.
Strata Critical Medical, Inc. is dedicated to supporting healthcare providers throughout the United States by offering swift logistical management and specialized medical assistance. A significant part of their operations involves the movement of human organs for transplant, utilizing both aerial and ground transportation methods. Founded in 2014, the organization previously operated under the name Blade Air Mobility, Inc. and is set to officially change its name to Strata Critical Medical, Inc. in August of 2025. Its primary corporate office is located in New York, New York.
SRTA Company Deck
SRTA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a largely positive picture driven by robust clinical growth, accretive bolt-on acquisitions, stronger-than-expected revenue and raised full-year guidance, and consecutive quarters of cash generation. These positives are tempered by near-term softness in Logistics (a ~3% revenue headwind from one customer), margin pressure from fuel pass-through mechanics and maintenance, and working-capital/transaction-related cash drag. Management provided concrete mitigation plans for Logistics margins and expects recovery in the back half of the year, supporting a constructive outlook.View all SRTA earnings summariesSRTA Stock 12 Month Forecast
Average Price Target
$9.50
▲(88.49% Upside)
Technical Analysis
Ownership Overview
14.23% Insiders
12.45% Mutual Funds
4.46% Other Institutional Investors
60.21% Public Companies and
Individual Investors